Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL9069511 | 0.89 | GLA (0.48) | GLAPOLBTSHRLMNAALDH1A1 | |
| SCHEMBL13853557 | 0.82 | GLA (0.51) | GLAPOLBTSHRLMNAALDH1A1 | |
| SCHEMBL18909475 | 0.82 | ATM (0.52) | POLBLMNAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL13188548 | 0.82 | ATM (0.58) | POLBLMNAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL13645749 | 0.81 | GLA (0.54) | GLAPOLBTSHRLMNAALDH1A1 | |
| SCHEMBL14079952 | 0.81 | TSHR (0.54) | GLAPOLBTSHRLMNAALDH1A1 | |
| Dimethylamine SCHEMBL27882636 | 0.81 | TSHR (0.57) | GLAPOLBTSHRLMNAALDH1A1 | |
| SCHEMBL25676935 | 0.80 | LMNA (0.53) | GLAPOLBTSHRLMNAALDH1A1 | |
| SCHEMBL1484933 | 0.80 | L3MBTL1 (0.53) | GLAPOLBTSHRLMNAALDH1A1 | |
| SCHEMBL20693526 | 0.80 | ATM (0.56) | ALDH1A1L3MBTL1HTTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| WO-2010100144-A1 | FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20090221458-A1 | SUCCINIC ACID SEMI-AMIDES AS ANTI-CORROSIVE AGENTS | CAMENZIND HUGO | 2009-09-03 | — | — | US | disclosed |
| US-5693619-A | ENZYME INHIBITORS; ADMINISTERED TO TREAT CONGESTIVE HEART FAILURE AND HYPERTENSION | BOEHRINGER INGELHEIM (CANADA), LTD. (CA) | 1997-12-02 | — | — | US | disclosed |
| EP-0589445-B1 | Renin Inhibiting N-(2-Amino-2-oxoethyl)Butanediamide Derivatives | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1997-01-15 | — | — | EP | disclosed |
| US-5541163-A | HYPOTENSIVE AGENTS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-07-30 | — | — | US | disclosed |
| WO-1994007846-A1 | RENIN INHIBITING N-(2-AMINO-2-OXOETHYL)BUTANEDIAMIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-04-14 | — | — | WO | disclosed |
| EP-0589445-A1 | Renin Inhibiting N-(2-Amino-2-oxoethyl)Butanediamide Derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | GLA 3355/4885POLB 1546/4885TSHR 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.